| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC1765 |
| Trial ID | NCT03244306 |
| Disease | Leukemia | Lymphoma |
| Altered gene | CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD22 CAR-T cells |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma |
| Year | 2017 |
| Country | United States |
| Company sponsor | Seattle Children's Hospital |
| Other ID(s) | PLAT-04 |
| Cohort 1 | |||||||||
|
|||||||||